Valneva Appoints Dipal Patel as Chief Commercial Officer
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member. With this newly created role, Valneva strengthens its management team with a recognized commercial industry leader as the Company advances its chikungunya vaccine candidate towards potential market entry in 2023.
Ms. Patel is an established commercial leader with over 23 years of experience in the pharmaceutical sector covering commercial strategy, execution, market access and lifecycle management. Over her career, she has held roles of increasing responsibilities across multiple countries including the United States, Australia, Belgium, Singapore, Thailand, and the European and emerging markets regions. Since 2019, Ms. Patel has been Global Commercial Head of GSK’s shingles vaccine (Shingrix®), leading a global cross-functional team establishing it as a global brand with significant worldwide expansion.
Thomas Lingelbach, Chief Executive Officer of Valneva, said, “Dipal’s addition to our team represents an important and timely step forward in strengthening Valneva’s commercial and strategic leadership. As the travel industry recovers, Dipal will ensure we are further growing our commercial business and preparing the best market access and launch for our chikungunya vaccine candidate. We are excited to leverage the wealth of knowledge, expertise, and insights she brings, and we look forward to her contributions to the growth and strategic development of the Company.”
Ms. Patel, newly appointed Chief Commercial Officer of Valneva, stated, “The last few years have put an increasing focus on the importance of vaccine preventable diseases. I am excited to be part of an organization with a strong vision to address some of the highest unmet medical needs in infectious diseases. I look forward to working with my new team to drive Valneva’s growth and excel in the upcoming launch and commercialization of our chikungunya vaccine candidate.”
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease and the chikungunya virus.
Media & Investor Contacts
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099